NeoGenomics, Inc. (NASDAQ:NEO) Stock Has Average Target Price of $20.88

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $20.88.

Several research firms recently commented on NEO. Craig Hallum restated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, July 29th. Wall Street Zen cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research cut shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Needham & Company LLC boosted their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Finally, Benchmark increased their target price on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th.

NeoGenomics Stock Performance

NEO opened at $17.38 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.53 and a quick ratio of 3.35. The business has a fifty day simple moving average of $17.68 and a 200 day simple moving average of $12.82. NeoGenomics has a 1 year low of $7.07 and a 1 year high of $20.15. The company has a market capitalization of $2.25 billion, a PE ratio of -69.52 and a beta of 1.79.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. NeoGenomics had a negative return on equity of 0.99% and a negative net margin of 4.10%. The firm had revenue of $209.25 million for the quarter, compared to analysts’ expectations of $206.70 million. During the same quarter last year, the business earned $0.03 EPS. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. Research analysts expect that NeoGenomics will post -0.09 EPS for the current year.

Institutional Investors Weigh In On NeoGenomics

Several institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP bought a new position in NeoGenomics during the 1st quarter worth $45,725,000. First Light Asset Management LLC raised its holdings in NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after acquiring an additional 2,549,545 shares in the last quarter. American Capital Management Inc. acquired a new position in NeoGenomics in the 2nd quarter valued at $32,648,000. Granite Investment Partners LLC bought a new stake in shares of NeoGenomics during the 1st quarter valued at $5,583,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of NeoGenomics during the 2nd quarter valued at $10,744,000. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics News Summary

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
• Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
• Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
• Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

About NeoGenomics

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.